600 patients66,869 observations120 daysLIVE

Patient P-01708

Synthetic patientNBL-101 · Day 116 · 35–44 · F · baseline S07Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
54%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S07
  2. Day 77 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 82 CR-01 recommendedClinician Review CR-01
  4. Day 83 Patient acceptedStarted CR-01 in the companion
  5. Day 88 Deterioration detected before clinical escalationClinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 77.

Primary contributors, last 14 days
  • Toxicity+7
  • Treatment adherence+5
  • GI instability-4
  • Inflammatory activity+3

What helped?

  • Clinician Review CR-01Day 82
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
63%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 84% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
57.4/100
improving · -11.3 vs previous 14 d
Toxicity
Blood
50.7/100
worsening · +4.7 vs previous 14 d
Sleep quality
Wearable
57.1/100
improving · +9.8 vs previous 14 d
Energy level
Daily log
3.2/10
improving · +0.7 vs previous 14 d
Stress level
Daily log
7.2/10
improving · -0.3 vs previous 14 d
Steps
Wearable
487
improving · +232 vs previous 14 d
Adherence
Companion
69.8 %
stable · +0.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 39 from the failing basin, 54 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 125 similar · onset 8 d · confidence 61%
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 64%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 64%
Would not help
  • Keep simple carbs low
    GI +5.5 next day on high-intake days · n 22
  • Keep histamine low
    GI +5.3 next day on high-intake days · n 20
  • Keep fat low
    GI +5.1 next day on high-intake days · n 18
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Simple carbohydrates
    +5.5detractor · 95%
  • Histamine load
    +5.3detractor · 95%
  • Dietary fat load
    +5.1detractor · 95%
  • Alcohol
    +0.3no signal · 15%
  • Insoluble fibre
    +0.2no signal · 15%
  • Spicy / capsaicin
    +0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 57 and rising
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 25/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 54
  • Autonomic recovery 45
    • WearableResting HR 83 bpm
    • Wearable487 steps/day
  • Drug metabolism and exposure 20
    • BloodToxicity index 51
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2 · butyrate capacity 25/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
52 ms
Sleep
6.9 h
Steps
1,030
Resting HR
82 bpm
Daily log: GI score 57, nutritional resilience 38, adherence 70.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0137140%S06CR-01improved63
P-0183537%S17CR-01improved56
P-0187737%S01CR-01improved67
P-0138836%S17CR-01improved59
P-0169634%S20CR-01improved59
P-0144231%S13CR-01improved61
P-0143023%S05CR-01improved54
P-0176723%S14DT-01no change63
P-0134222%S11DT-01improved48
P-0172543%S18GI-04no change56
P-0169941%S04GI-04improved69
P-0143837%S14GI-04improved56